Prospective Assessment of Pituitary Function in Patients with Macroprolactinoma Treated with Cabergoline.

Prospective Assessment of Pituitary Function in Patients with Macroprolactinoma Treated with Cabergoline.

Detalles Bibliográficos
Autores principales:	Karavitaki, N, Wass, J
Formato:	Conference item
Publicado:	2010

Ejemplares similares

Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
por: Karavitaki, N, et al.
Publicado: (2013)

Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
por: Karavitaki, N, et al.
Publicado: (2013)

The outcome of macroprolactinomas resistant to dopamine agonists
por: Coculescu, M, et al.
Publicado: (2005)

Efficacy and safety of rapid escalation of cabergoline in comparison to conventional regimen for macroprolactinoma: A prospective, randomized trial
por: Ashu Rastogi, et al.
Publicado: (2012-01-01)

Clinical Outcome of Invasive Pituitary Prolactinomas Treated with Cabergoline
por: Bassam M Flamerz Arkawazi
Publicado: (2020-01-01)

Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.
por: Herring, N, et al.
Publicado: (2009)

A case of macroprolactinoma encasing an internal carotid artery aneurysm, presenting as pituitary apoplexy.
por: Soni, A, et al.
Publicado: (2008)

Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes.
por: Lambert, K, et al.
Publicado: (2017)

Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes
por: Lambert, K, et al.
Publicado: (2017)

Cabergoline-Induced Pneumocephalus Following Treatment for Giant Invasive Macroprolactinoma Presenting With Spontaneous Cerebrospinal Fluid Rhinorrhea
por: Souha S Elabd, et al.
Publicado: (2018-02-01)

Cabergoline-induced mania in a patient of pituitary microadenoma
por: Satyakam Mohapatra, et al.
Publicado: (2017-01-01)

An aggressive cabergoline-resistant, temozolomide-responsive macroprolactinoma due to a germline SDHB pathogenic variant in the absence of paraganglioma or pheochromocytoma
por: Ali S. Alzahrani, et al.
Publicado: (2023-12-01)

A patient with a germline SDHB mutation presenting with an isolated pituitary macroprolactinoma
por: Michelle Maher, et al.
Publicado: (2018-07-01)

Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma?
por: Reddy, R, et al.
Publicado: (2011)

Non-adenomatous pituitary tumours.
por: Karavitaki, N, et al.
Publicado: (2009)

Diagnosis and management of prolactinomas and non-functioning pituitary adenomas.
por: Rogers, A, et al.
Publicado: (2014)

Nonfunctioning pituitary adenomas: the Oxford experience.
por: Wass, J, et al.
Publicado: (2009)

Growth hormone replacement in patients with non-functioning pituitary adenoma treated solely by surgery is not associated with increased risk of tumour recurrence.
por: Arnold, J, et al.
Publicado: (2008)

GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence.
por: Arnold, JR, et al.
Publicado: (2009)

The postoperative monitoring of nonfunctioning pituitary adenomas.
por: Wass, J, et al.
Publicado: (2011)

The postoperative monitoring of nonfunctioning pituitary adenomas
por: Wass, J, et al.
Publicado: (2011)

Pituitary apoplexy in an adolescent male with macroprolactinoma presenting as middle cerebral artery territory infarction
por: Pankaj Agrawal, et al.
Publicado: (2022-12-01)

Treatment of pituitary tumors: history.
por: Thanabalasingham, G, et al.
Publicado: (2005)

Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience
por: Guadalupe Vargas-Ortega, et al.
Publicado: (2022-07-01)

Successful Management of a Giant Pituitary Lactosomatotroph Adenoma Only with Cabergoline
por: Emre Bozkirli, et al.
Publicado: (2013-01-01)

Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma
por: DL Goede, et al.
Publicado: (2006-04-01)

The modern management of macroprolactinomas.
por: Grossman, A
Publicado: (1991)

Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction
por: Tania Sundra, et al.
Publicado: (2024-03-01)

No link to cardiac valvulopathy was seen in cabergoline treated patients
por: K Dharshini, et al.
Publicado: (2012-10-01)

Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: incidence, radiological, and clinicopathological features.
por: Suliman, S, et al.
Publicado: (2007)

MANAGEMENT OF ENDOCRINE DISEASE: Pituitary tumour apoplexy.
por: Capatina, C, et al.
Publicado: (2014)

Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
por: Barber, T, et al.
Publicado: (2011)

Reply to Commentary on "Pituitary apoplexy in an adolescent male with macroprolactinoma presenting as middle cerebral artery territory infarction"
por: Pankaj Agrawal, et al.
Publicado: (2023-03-01)

Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report
por: Shaojian Lin, et al.
Publicado: (2022-08-01)

A Combination of Exercise and Therapy with Cabergoline Attenuate Disturbances of Pituitary-Gonadal Hormones in Hyperprolactinemic Male Patients
por: Mohammad Fayiz AbuMoh'd, et al.
Publicado: (2020-07-01)

Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).
por: Fernandez, A, et al.
Publicado: (2010)

Macroprolactinoma in an adolescent female with primary amenorrhoea
por: Ning Zhang, et al.
Publicado: (2024-12-01)

Pituitary apoplexy in non-functioning pituitary adenomas: Long term follow up is important because of significant numbers of tumour recurrences
por: Pal, A, et al.
Publicado: (2011)

Pituitary apoplexy in non-functioning pituitary adenomas: long term follow up is important because of significant numbers of tumour recurrences.
por: Pal, A, et al.
Publicado: (2011)

Macroprolactinoma resistente aos agonistas dopaminérgicos: relato de caso Macroprolactinoma resistant to dopamine agonists: a case report
por: Rosana Maria dos Reis, et al.
Publicado: (2004-09-01)